◎ Sugi Atlas

Atlas / Disease / Chronic graft versus host disease

Chronic graft versus host disease

disease
On this page

Also known as chronic GVHDgraft versus host disease, chronicGVHD, chronic

Summary

Chronic graft versus host disease (MONDO:0020547) is a disease with 8 GWAS associations across 6 studies and 123 clinical trials. Top therapeutic interventions include belumosudil, fostamatinib, and axatilimab. A subtype of graft versus host disease — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

  • GWAS associations: 8
  • Phenotypes (HPO): 53
  • Clinical trials: 123

Clinical features

Signs & symptoms

Clinical features (HPO)

53 HPO clinical features (Orphanet curated; top 50 by frequency):

HPO IDTermFrequency
HP:0001058Poor wound healingVery frequent (80-99%)
HP:0001072Thickened skinVery frequent (80-99%)
HP:0007432Intermittent generalized erythematous papular rashVery frequent (80-99%)
HP:0000217XerostomiaFrequent (30-79%)
HP:0000495Recurrent corneal erosionsFrequent (30-79%)
HP:0000613PhotophobiaFrequent (30-79%)
HP:0001000Abnormality of skin pigmentationFrequent (30-79%)
HP:0001097Keratoconjunctivitis siccaFrequent (30-79%)
HP:0001596AlopeciaFrequent (30-79%)
HP:0001806OnycholysisFrequent (30-79%)
HP:0002110BronchiectasisFrequent (30-79%)
HP:0002719Recurrent infectionsFrequent (30-79%)
HP:0002910Elevated circulating hepatic transaminase concentrationFrequent (30-79%)
HP:0008404Nail dystrophyFrequent (30-79%)
HP:0010783ErythemaFrequent (30-79%)
HP:0012537Food intoleranceFrequent (30-79%)
HP:0000142Abnormality of the vaginaOccasional (5-29%)
HP:0000790HematuriaOccasional (5-29%)
HP:0001324Muscle weaknessOccasional (5-29%)
HP:0001369ArthritisOccasional (5-29%)
HP:0001371Flexion contractureOccasional (5-29%)
HP:0001541AscitesOccasional (5-29%)
HP:0001741PhimosisOccasional (5-29%)
HP:0001824Weight lossOccasional (5-29%)
HP:0001876PancytopeniaOccasional (5-29%)
HP:0002014DiarrheaOccasional (5-29%)
HP:0002015DysphagiaOccasional (5-29%)
HP:0002018NauseaOccasional (5-29%)
HP:0002020Gastroesophageal refluxOccasional (5-29%)
HP:0002027Abdominal painOccasional (5-29%)
HP:0002031Abnormal esophagus morphologyOccasional (5-29%)
HP:0002039AnorexiaOccasional (5-29%)
HP:0002043Esophageal strictureOccasional (5-29%)
HP:0002094DyspneaOccasional (5-29%)
HP:0002107PneumothoraxOccasional (5-29%)
HP:0002113Pulmonary infiltratesOccasional (5-29%)
HP:0002202Pleural effusionOccasional (5-29%)
HP:0002829ArthralgiaOccasional (5-29%)
HP:0003326MyalgiaOccasional (5-29%)
HP:0004791Esophageal ulcerationOccasional (5-29%)
HP:0006536Airway obstructionOccasional (5-29%)
HP:0011946Bronchiolitis obliteransOccasional (5-29%)
HP:0012181Entrapment neuropathyOccasional (5-29%)
HP:0012344MorpheaOccasional (5-29%)
HP:0012531PainOccasional (5-29%)
HP:0012735CoughOccasional (5-29%)
HP:0025270Abnormal esophagus physiologyOccasional (5-29%)
HP:0030828WheezingOccasional (5-29%)
HP:0100537FasciitisOccasional (5-29%)
HP:0100577Urinary bladder inflammationOccasional (5-29%)

Identifiers

Disease identifiers

FieldValue
Canonical namechronic graft versus host disease
Mondo IDMONDO:0020547
Orphanet99921
ICD-10-CMD89.811
ICD-11621183043
NCITC4981
SNOMED CT402356004
UMLSC0867389
MedGen167851
GARD0010964
MedDRA10066261
Is cancer (heuristic)no

Also known as: chronic GVHD · graft versus host disease, chronic · GVHD, chronic

Data availability: 8 GWAS associations (6 studies).

Disease family

This is a subtype of graft versus host disease. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › immune system disorder › graft versus host disease › chronic graft versus host disease

Related subtypes (1): acute graft versus host disease

Genetics & variants

GWAS landscape

8 GWAS associations across 6 studies. Top hits map to 2 distinct genes (as reported by GWAS).

Top associations by p-value

rsIDp-valueGeneRisk alleleOdds ratio
rs27180374e-09GPR141C0.72
rs790809066e-08LINC00882A0.46
rs800007742e-07THRAP3P1 - STT3BC7.53
rs26131932e-07RPS3AP17 - PCDH7G3.4
rs45667643e-07TMEM174 - LINC02230A1.31
rs782929724e-07Metazoa_SRP - LRATD1C1.45
rs2836034e-07ARHGEF28 - LINC02122T1.2
rs341421624e-07XYLT1 - RPL7P47C6.23

Top studies (by case count)

StudyLead authorYearCasesControlsTitle
GCST90102559Martin PJ202200Genetic Associations with Immune-mediated Outcomes after Allogeneic Hematopoietic Cell Transplantation.
GCST90102565Martin PJ202200Genetic Associations with Immune-mediated Outcomes after Allogeneic Hematopoietic Cell Transplantation.
GCST90102571Martin PJ202200Genetic Associations with Immune-mediated Outcomes after Allogeneic Hematopoietic Cell Transplantation.
GCST90102577Martin PJ202200Genetic Associations with Immune-mediated Outcomes after Allogeneic Hematopoietic Cell Transplantation.
GCST90102583Martin PJ202200Genetic Associations with Immune-mediated Outcomes after Allogeneic Hematopoietic Cell Transplantation.
GCST90102589Martin PJ202200Genetic Associations with Immune-mediated Outcomes after Allogeneic Hematopoietic Cell Transplantation.

Variant details and genetic-evidence tiers

Tier distribution (top 50 variants)

TierVariants
Tier 1: coding0
Tier 2: splice/UTR0
Tier 3: regulatory0
Tier 4: intronic/intergenic8

MAF distribution

BucketVariants
common (>=0.05)5
low_freq (0.01-0.05)3
rare (<0.01)0
unknown0

Functional consequences

ConsequenceCount
intron_variant4
intergenic_variant4

Top variants

rsIDChrPosAllelesMAFConsequenceGenep-valueTier
rs2718037737738244G>A,C,T0.297intron_variantGPR1414e-09Tier 4: intronic/intergenic
rs790809063106637342T>A0.017intron_variantLINC008826e-08Tier 4: intronic/intergenic
rs80000774331476044T>C0.041intergenic_variantTHRAP3P1 - STT3B2e-07Tier 4: intronic/intergenic
rs2613193430236054T>G0.017intergenic_variantRPS3AP17 - PCDH72e-07Tier 4: intronic/intergenic
rs4566764573197270G>A0.453intergenic_variantTMEM174 - LINC022303e-07Tier 4: intronic/intergenic
rs78292972214626004G>A,C0.069intron_variantMetazoa_SRP - LRATD14e-07Tier 4: intronic/intergenic
rs283603573949654C>T0.311intron_variantARHGEF28 - LINC021224e-07Tier 4: intronic/intergenic
rs341421621617739328T>A,C0.072intergenic_variantXYLT1 - RPL7P474e-07Tier 4: intronic/intergenic

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 123.

Phase distribution (across all retrieved trials)

PhaseTrials
PHASE255
Not specified28
PHASE1/PHASE215
PHASE110
PHASE37
PHASE43
PHASE2/PHASE33
EARLY_PHASE12

Top trials by phase / activity

NCTPhaseStatusTitle
NCT07135973PHASE4NOT_YET_RECRUITINGA Study to Investigate Safety of Belumosudil in Participants Aged 12 Years and Above, With Chronic Graft-versus-host Disease (cGVHD)
NCT03190733PHASE4UNKNOWNA Optimal Anti-Thymoglobuline (ATG) Dose Decrease cGVHD But Not Increase Leukemia Relapse for Haplo-HSCT
NCT06616415PHASE4COMPLETEDA Clinical Study to Evaluate the Pharmacokinetics, Efficacy, and Safety of Belumosudil in Chinese Adolescents With cGVHD Who Have Had an Inadequate Response to Glucocorticoids or Other Systemic Therapies
NCT01804686PHASE3RECRUITINGA Long-term Extension Study of PCI-32765 (Ibrutinib)
NCT06143891PHASE3ACTIVE_NOT_RECRUITINGA Study to Test an Oral Medicine, Belumosudil, in Combination With Corticosteroids in Participants at Least 12 Years of Age With Newly Diagnosed Chronic Graft Versus Host Disease.
NCT06263478PHASE3ACTIVE_NOT_RECRUITINGA Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Axatilimab Monotherapy in Japanese Participants With Recurrent or Refractory Active Chronic Graft-Versus-Host Disease
NCT06585774PHASE3RECRUITINGA Study to Evaluate Axatilimab and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease
NCT06821542PHASE3ACTIVE_NOT_RECRUITINGA Study to Evaluate Axatilimab Versus Best Available Therapy in Participants With Chronic Graft Versus Host Disease After at Least 2 Prior Lines of Systemic Therapy
NCT01106833PHASE2/PHASE3COMPLETEDChronic Graft-versus-Host Disease Treatment (BMT CTN 0801)
NCT01526850PHASE2/PHASE3UNKNOWNEfficacy and Safety Study of Allogenic Mesenchymal Stem Cells for Patients With Chronic Graft Versus Host Disease
NCT02291770PHASE3UNKNOWNTreatment of Chronic Graft-Versus-Host Disease With Mesenchymal Stromal Cells
NCT02959944PHASE3COMPLETEDIbrutinib in Combination With Corticosteroids vs Placebo in Combination With Corticosteroids in Participants With New Onset Chronic Graft Versus Host Disease (cGVHD)
NCT03584516PHASE2/PHASE3TERMINATEDGRAVITAS-309: Itacitinib and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease
NCT01366092PHASE2ACTIVE_NOT_RECRUITINGDaily IL-2 for Steroid-Refractory Chronic Graft-versus-Host-Disease
NCT02669251PHASE1/PHASE2ACTIVE_NOT_RECRUITINGAlvelestat (MPH966), an Oral Neutrophil Elastase Inhibitor, in Bronchiolitis Obliterans Syndrome After Allogeneic Hematopoietic Stem Cell Transplantation
NCT02918188PHASE2RECRUITINGTherapeutic Effects of Hydrogen on Steroid-refractory/or Steroid-dependent cGVHD
NCT04202835PHASE2ACTIVE_NOT_RECRUITINGATG Plus PTCy vs ATG for CGVHD Prophylaxis
NCT04640025PHASE2ACTIVE_NOT_RECRUITINGA Rollover Study to Provide Continued Treatment for Participants Previously Enrolled in Studies of Itacitinib
NCT04710576PHASE2ACTIVE_NOT_RECRUITINGA Study of Axatilimab at 3 Different Doses in Participants With Chronic Graft Versus Host Disease (cGVHD)
NCT04944043PHASE1/PHASE2ACTIVE_NOT_RECRUITINGA Study of TQ05105 in Patients With Chronic Graft Versus Host Disease
NCT05922761PHASE2RECRUITINGBElumosudil for Bronchiolitis Obliterans Prevention/Therapy (BEBOP)
NCT05996627PHASE2RECRUITINGBelumosudil for the Pre-emptive Treatment of Patients With Chronic Graft Versus Host Disease
NCT06046248PHASE2RECRUITINGBelumosudil and Rituximab for Primary Treatment of Chronic Graft-Versus-Host-Disease
NCT06169722PHASE1/PHASE2ACTIVE_NOT_RECRUITINGTDI01 Suspension in the Treatment of Chronic Graft-versus-host Disease (cGVHD))
NCT06300320PHASE2RECRUITINGA Clinical Trial of TQ05105 Tablets in the Treatment of Chronic Graft-versus-host Disease
NCT06388564PHASE2ACTIVE_NOT_RECRUITINGA Study to Evaluate the Safety and Efficacy of Axatilimab in Combination With Ruxolitinib in Participants With Newly Diagnosed Chronic Graft-Versus-Host Disease
NCT06663722PHASE2RECRUITINGAxatilimab in Combination With Extracorporeal Photopheresis (ECP) in Chronic Graft-versus-Host Disease
NCT06843408PHASE1/PHASE2RECRUITINGA Ph1b/2 Study of Axatilimab Monotherapy in Chinese Participants With Recurrent or Refractory cGVHD
NCT07011810PHASE2RECRUITINGAxatilimab for Sclerotic Chronic Graft-versus-Host Disease
NCT07012304PHASE1/PHASE2RECRUITINGGecacitinib for cGVHD: Safety and Efficacy in Patients After ≥2 Lines of Prior Therapy
NCT07116031PHASE2RECRUITINGA Study of Belumosudil in Children With Chronic Graft Versus Host Disease (schoolROCK)
NCT07124078PHASE2RECRUITINGA Study to Evaluate Axatilimab Versus Best Available Therapy in Pediatric Participants With Chronic Graft-Versus-Host Disease After at Least 2 Prior Lines of Systemic Therapy (AGAVE-256)
NCT07606703PHASE2RECRUITINGA Prospective Study of Madecassoside Tablets in Sclerotic Chronic Graft-versus-Host Disease After Allo-HSCT
NCT00271869PHASE2UNKNOWNTreatment of Chronic GVHD of Liver or Lungs by ECP
NCT00397332PHASE1/PHASE2COMPLETEDAlefacept for Chronic Graft Versus Host Disease
NCT00656058PHASE2COMPLETEDMontelukast to Treat Bronchiolitis Obliterans
NCT00815919PHASE2COMPLETEDBortezomib Plus Prednisone for Initial Therapy of Chronic Graft Versus Host Disease
NCT01028313PHASE2WITHDRAWNA Study of Panobinostat (LBH589) as Second-Line Therapy in Patients With Chronic Graft-Versus-Host Disease
NCT01158105PHASE2UNKNOWNBortezomib for the Treatment of Refractory Chronic Graft-vs-Host Disease(cGVHD)
NCT01161628PHASE2COMPLETEDRituximab for the Primary Treatment of Denovo Extensive Chronic Graft Versus Host Disease (GVHD)

Drugs tested across these trials (top 30)

MoleculeMax phaseTrials referencing
BELUMOSUDIL49
FOSTAMATINIB46
AXATILIMAB45
ALEFACEPT42
IBRUTINIB42
LEFLUNOMIDE42
ABATACEPT41
BARICITINIB41
BECLOMETHASONE DIPROPIONATE41
CARFILZOMIB41
GLASDEGIB41
IXAZOMIB CITRATE41
OFATUMUMAB41
PANOBINOSTAT41
PONESIMOD41
POSACONAZOLE41
TAFASITAMAB41
VISMODEGIB41
VORICONAZOLE41
ITACITINIB34
CATEQUENTINIB31
IVARMACITINIB SULFATE31
ADRIXETINIB21
ALVELESTAT21
BECLOMETHASONE21
HYDROGEN21
CHEMBL541522909
CHEMBL1572007
CHEMBL364796402
CHEMBL446620502

About this page

Generated deterministically by Sugi Atlas from primary biomedical databases via BioBTree. Every record on this page traces to a primary source.

Generated
Atlas version
v1.1.4
BioBTree
v2.0.2

Sources 24

This page pulls from 24 datasets indexed by BioBTree:

chembl_moleculecivic_evidenceclinical_trialsclinvardbsnpefogardgenccgwasgwas_studyhgncicd10cmicd11meddramedgenmeshmimmondomondochildmondoparentncitorphanetsctidumls